NCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
Clinical Trials
33 trialsNCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06083844 2026-03-04
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07261683 2025-12-19
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03029403 2025-09-19
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04387227 2025-09-18
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 2 Active not recruiting
NCT05920798 2025-06-22
FRAPPE
Mayo Clinic
Phase 1/2 Recruiting
NCT04919629 2025-05-11
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT04713514 2024-12-02
TEDOVA
ARCAGY/ GINECO GROUP
Phase 2 Active not recruiting
NCT03596281 2024-10-18
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT03732950 2024-04-15
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05368207 2024-03-13
Pemb-HT
University Health Network, Toronto
Phase NA Active not recruiting
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT02766582 2024-02-26
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT02901899 2024-02-20
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Northwestern University
Phase 2 Completed
NCT05746897 2024-01-26
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
Phase 1 Recruiting
NCT04417192 2023-07-06
OLAPem
National Cancer Center Hospital East
Phase 2 Completed
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03410784 2023-03-24
MITO28MaNGOov4
National Cancer Institute, Naples
Phase 2 Unknown
NCT03430700 2023-01-30
PROMPT
University College, London
Phase 2 Unknown
NCT03428802 2022-11-18
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02865811 2022-09-13
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03029598 2022-07-26
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1/2 Completed
NCT02499952 2022-07-11
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT02608684 2022-03-23
PemCiGem
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04375956 2021-12-20
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT02853318 2021-10-06
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown